UK Health Officials Investigate the Link Between Parkinson’s Medication and Impulsive Behaviours

The UK’s health regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has launched a comprehensive review into how information and warnings are provided for certain Parkinson’s medications. This move comes following reports of people developing life-changing addictions and impulsive behaviours, such as gambling or hypersexuality, after starting their treatment. The investigation focuses primarily on a group of drugs known as dopamine agonists. While these medications are highly effective at mimicking the effects of dopamine to improve movement and manage symptoms of Parkinson’s, they carry a known risk of triggering impulse control disorders. Data from the Parkinson’s Foundation suggests that as many as one in six people taking these specific drugs may experience these side effects. The challenge lies in how these drugs interact with the brain’s reward system. Because dopamine is heavily involved in how we process pleasure and motivation, stimulating these receptors can sometimes lead to obsessive shopping, binge eating, or intense urges that were never present before the medication was prescribed. For many, these changes occur without any prior history of addictive behaviour, making them particularly distressing for the individuals and their families. The MHRA’s Chief Safety Officer, Dr Alison Cave, emphasised that while these medicines have improved many lives, patient safety remains the top priority. The goal of the current assessment is to determine if regulatory action is needed to ensure both healthcare professionals and those living with Parkinson’s are fully aware of the risks before a prescription is written. Health officials are urging anyone who notices a shift in behaviour—whether it is the person taking the medication, a family member, or a carer—to speak to their doctor immediately. Because these behaviours are side effects of the medication rather than a personal choice, adjusting the dosage or changing the type of treatment under medical supervision can often resolve the issue. As this review progresses, the focus remains on balancing the clear benefits of dopamine agonists with the necessity for transparent communication, ensuring that those managing Parkinson’s can do so with the best possible support and information. Substitutions 🍒 If dopamine agonists are causing issues, doctors may consider Levodopa-based treatments. 🍒 Monoamine oxidase-B (MAO-B) inhibitors can sometimes be used as an alternative or supplementary option. 🍒 Amantadine or anticholinergics might be suggested depending on the specific symptoms being managed.